第二章。合成多肽在欧洲的监管前景

René Thürmer
{"title":"第二章。合成多肽在欧洲的监管前景","authors":"René Thürmer","doi":"10.1039/9781788016445-00031","DOIUrl":null,"url":null,"abstract":"Synthetic peptides are of increasing importance as a class of substances used in medicinal products and the number of applications for marketing authorization has increased steadily in recent years. Based on European quality guidelines, international quality guidelines and European Pharmacopoeia (Ph. Eur.) requirements, it is discussed which data are relevant for synthetic peptides. The requirements for both marketing authorization applications and for clinical studies are addressed.","PeriodicalId":20009,"journal":{"name":"Peptide Therapeutics","volume":"86 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Chapter 2. Regulatory Perspective on Synthetic Peptides in Europe\",\"authors\":\"René Thürmer\",\"doi\":\"10.1039/9781788016445-00031\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Synthetic peptides are of increasing importance as a class of substances used in medicinal products and the number of applications for marketing authorization has increased steadily in recent years. Based on European quality guidelines, international quality guidelines and European Pharmacopoeia (Ph. Eur.) requirements, it is discussed which data are relevant for synthetic peptides. The requirements for both marketing authorization applications and for clinical studies are addressed.\",\"PeriodicalId\":20009,\"journal\":{\"name\":\"Peptide Therapeutics\",\"volume\":\"86 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-08-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Peptide Therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1039/9781788016445-00031\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Peptide Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1039/9781788016445-00031","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

合成肽作为一类用于医药产品的物质越来越重要,近年来申请上市许可的数量稳步增加。根据欧洲质量指南、国际质量指南和欧洲药典(Ph. Eur.)的要求,讨论了合成肽的相关数据。解决了上市许可申请和临床研究的要求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Chapter 2. Regulatory Perspective on Synthetic Peptides in Europe
Synthetic peptides are of increasing importance as a class of substances used in medicinal products and the number of applications for marketing authorization has increased steadily in recent years. Based on European quality guidelines, international quality guidelines and European Pharmacopoeia (Ph. Eur.) requirements, it is discussed which data are relevant for synthetic peptides. The requirements for both marketing authorization applications and for clinical studies are addressed.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信